VC
Value Add VC
⚡HomePulse⚡Helpful Apps📝Blog🤝Partner
Illustration for: Europe Posts Its Best VC Quarter in 4 Years as UK Leads
Value Add VC/Pulse/IPO$24B Q2 2026 European funding

Europe Posts Its Best VC Quarter in 4 Years as UK Leads

European startups raised $24 billion in Q2 2026, up two-thirds year-over-year, with UK startups alone pulling in more than $10 billion -- the region's third-largest quarter on record.

By the Numbers

$24 billion
Q2 European funding
~2/3 vs Q2 2025
YoY growth
$10 billion+
UK Q2 funding
3rd-largest ever
UK quarter ranking
<$500 million
Below 2021 UK peak
TC
Trace Cohen
Early-stage VC & angel · Founder, New York Venture Partners
July 9, 2026
2 min read
ShareXLinkedInEmail

THE RUNDOWN

1

European startups raised $24 billion in Q2 2026, according to Crunchbase data -- the region's strongest quarter in four years, up roughly a third quarter-over-quarter and about two-thirds higher than the $14.4 billion raised in Q2 2025

2

UK startups captured an outsized share of that growth, raising more than $10 billion in the quarter -- the third-largest UK funding quarter on record, sitting less than $500 million below the country's 2021 peak

3

The quarter's billion-dollar-plus rounds skewed heavily AI: Alphabet-owned drug developer Isomorphic Labs (spun out of DeepMind), green-steel manufacturer Stegra, humanoid and industrial robotics company Neura Robotics, and Ineffable Intelligence, an AI lab founded by former DeepMind researchers, all closed mega-rounds

4

European M&A activity picked up in parallel through Q1 and Q2 even as public-market exits stayed subdued, reinforcing that Europe's capital-formation engine is currently running on private mega-rounds and strategic sales rather than IPOs

TC

The VC Read · Trace's Take

Trace Cohen

The UK sitting within $500M of its 2021 peak while overall European deal count keeps shrinking is the same barbell story playing out everywhere else in venture right now -- more capital, fewer winners. If you're building outside London with an AI or deep-tech story, the data still says the money is there; if you're building a generalist SaaS company anywhere in Europe, this quarter's headline number isn't really about you.

Analysis

European startups raised $24 billion in the second quarter of 2026, according to Crunchbase data -- the region's strongest quarter in four years, up roughly a third from Q1 and about two-thirds higher than the $14.4 billion raised in the same quarter a year earlier. The acceleration confirms that Europe's funding rebound, which first showed up in Q1 data, wasn't a one-quarter blip.

The UK did more than its proportional share of the lifting: British startups raised more than $10 billion in the quarter, the country's third-largest funding quarter on record and less than $500 million shy of its 2021 peak, a period widely regarded as the top of the last venture cycle. That puts the UK's current quarter within striking distance of its all-time high even as much of the rest of Europe's funding market remains well below 2021 levels.

The composition of the quarter's biggest rounds tells the same AI-concentration story playing out globally: Alphabet-owned drug developer Isomorphic Labs, spun out of DeepMind, Swedish green-steel manufacturer Stegra, German industrial and humanoid robotics company Neura Robotics, and Ineffable Intelligence -- an AI lab founded by former DeepMind researchers -- all closed billion-dollar-plus rounds. Three of the four have direct AI or DeepMind lineage, underscoring how concentrated Europe's mega-round activity has become around AI-adjacent deep tech rather than spreading across sectors.

“That puts the UK's current quarter within striking distance of its all-time high even as much of the rest of Europe's funding market remains well below 2021 levels.”

European M&A activity picked up in parallel through both Q1 and Q2, even as public-market IPO exits stayed comparatively subdued -- consistent with the broader pattern that Europe's most realistic exit path right now runs through strategic acquisition rather than a public listing, a dynamic reinforced by the region's thin IPO pipeline relative to the US market's current appetite for AI-infrastructure debuts like SK Hynix's.

For European founders, the data argues that raising a large round in 2026 is genuinely more achievable than it's been in years, provided the company has a credible AI, deep-tech or climate-infrastructure story -- Isomorphic Labs, Stegra and Neura Robotics all fit that mold rather than being generalist software plays. For US and global investors weighing European exposure, the UK's near-2021-peak quarter is a specific, actionable signal: London's ecosystem is currently absorbing a disproportionate share of Europe's AI-era capital relative to Berlin, Paris or other continental hubs.

The bear case: a handful of mega-rounds concentrated in AI-adjacent deep tech can flatter an aggregate funding number without reflecting broader ecosystem health -- overall European deal count has fallen even as total dollars raised have grown, meaning fewer companies are capturing more of the available capital, the same barbell pattern showing up in US data. What to watch next: whether Q3 sustains this growth rate or reflects a pullback once the current wave of mega-rounds cycles through, and whether any UK or European AI company tests the public markets given the strength of the private funding environment.

ShareXLinkedInEmail

Reported by Crunchbase News · Analysis by Value Add Pulse.

← Back to Pulse

THE WIRE in your inbox— Tech, startup & VC news with Trace's take. Free, no spam.

Read Next

IPO· Aug 7, 2026

SpaceX Swings From Post-Earnings Drop to 16% Rally

Illustration for: SpaceX Swings From Post-Earnings Drop to 16% Rally
IPO$7.81B Q2 revenue

SpaceX Swings From Post-Earnings Drop to 16% Rally

SpaceX stock fell 8% after a Q2 earnings beat spooked investors on capex, then rallied 15.83% three days later as its first lockup expiration passed without heavy selling and the Cursor deal stayed on track.

IPO· Aug 7, 2026

BlossomHill Prices Upsized $150M IPO, Debuts on Nasdaq

Illustration for: BlossomHill Prices Upsized $150M IPO, Debuts on Nasdaq
IPO$150M IPO

BlossomHill Prices Upsized $150M IPO, Debuts on Nasdaq

BlossomHill Therapeutics priced an upsized IPO at $16 a share for $150M and began trading on Nasdaq under BLSM, more than 50% above the $100M target Pulse flagged when the company first filed.

IPO· Aug 7, 2026

BofA's Sell Signal Hits Highest Level Since 2021

Illustration for: BofA's Sell Signal Hits Highest Level Since 2021
IPO

BofA's Sell Signal Hits Highest Level Since 2021

Bank of America's Bull & Bear sentiment indicator jumped to 9.7 -- its highest reading since 2021 and above the firm's own 8.0 sell-signal threshold -- even as the S&P 500 and Nasdaq both rallied Friday on weak jobs data.

@Trace_Cohen·t@nyvp.com